{
    "id": 30348,
    "fullName": "LAMTOR1 - AKT1",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "LAMTOR1-AKT1 results from the fusion of LAMTOR1 and AKT1, leading to constitutive Akt1 phosphorylation and membrane localization in patient and patient-derived samples and cultured cells (PMID: 30877085). LAMTOR1-AKT1 has been identified in an indeterminate epitheloid neoplasm (PMID: 30877085).",
            "references": [
                {
                    "id": 15377,
                    "pubMedId": 30877085,
                    "title": "Patient-Driven Discovery, Therapeutic Targeting, and Post-Clinical Validation of a Novel AKT1 Fusion-Driven Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30877085"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 55004,
        "geneSymbol": "LAMTOR1",
        "terms": [
            "LAMTOR1",
            "C11orf59",
            "p18",
            "p27RF-Rho",
            "PDRO",
            "Ragulator1"
        ]
    },
    "variant": "LAMTOR1 - AKT1",
    "createDate": "06/17/2019",
    "updateDate": "06/17/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 207,
                "geneSymbol": "AKT1",
                "terms": [
                    "AKT1",
                    "AKT",
                    "CWS6",
                    "PKB",
                    "PKB-ALPHA",
                    "PRKBA",
                    "RAC",
                    "RAC-ALPHA"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 17332,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a pediatric patient with an indeterminate epithelioid tumor harboring a LAMTOR1-AKT1 fusion demonstrated reduced pain and tumor burden and decrease in CA-125 levels following treatment with Ipatasertib (GDC-0068), and patient-derived cells and xenograft models demonstrated sensitivity to growth inhibition by Ipatasertib (GDC-0068); however, the patient's CA-125 levels increased after 2 months of treatment and disease recurred (PMID: 30877085).",
            "molecularProfile": {
                "id": 32504,
                "profileName": "LAMTOR1 - AKT1"
            },
            "therapy": {
                "id": 747,
                "therapyName": "Ipatasertib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15377,
                    "pubMedId": 30877085,
                    "title": "Patient-Driven Discovery, Therapeutic Targeting, and Post-Clinical Validation of a Novel AKT1 Fusion-Driven Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30877085"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17348,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Rapamune (sirolimus) and Ipatasertib (GDC-0068) demonstrated an additive effect on growth inhibition of cells derived from a patient with an indeterminate epithelioid neoplasm harboring LAMTOR1-AKT1, in culture (PMID: 30877085).",
            "molecularProfile": {
                "id": 32504,
                "profileName": "LAMTOR1 - AKT1"
            },
            "therapy": {
                "id": 8462,
                "therapyName": "Ipatasertib + Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15377,
                    "pubMedId": 30877085,
                    "title": "Patient-Driven Discovery, Therapeutic Targeting, and Post-Clinical Validation of a Novel AKT1 Fusion-Driven Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30877085"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17347,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rapamune (sirolimus) inhibited growth of cells derived from a patient with an indeterminate epithelioid neoplasm harboring LAMTOR1-AKT1, in culture (PMID: 30877085).",
            "molecularProfile": {
                "id": 32504,
                "profileName": "LAMTOR1 - AKT1"
            },
            "therapy": {
                "id": 917,
                "therapyName": "Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15377,
                    "pubMedId": 30877085,
                    "title": "Patient-Driven Discovery, Therapeutic Targeting, and Post-Clinical Validation of a Novel AKT1 Fusion-Driven Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30877085"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17334,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MK-2206 did not inhibit AKT/mTORC signaling in cultured cells or xenograft models derived from a pediatric patient with an indeterminate epithelioid tumor harboring a LAMTOR1-AKT1 fusion, did not inhibit tumor growth in patient-derived xenograft (PDX) models, and inhibited patient-derived cell growth only at high doses in culture (PMID: 30877085).",
            "molecularProfile": {
                "id": 32504,
                "profileName": "LAMTOR1 - AKT1"
            },
            "therapy": {
                "id": 816,
                "therapyName": "MK2206",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 15377,
                    "pubMedId": 30877085,
                    "title": "Patient-Driven Discovery, Therapeutic Targeting, and Post-Clinical Validation of a Novel AKT1 Fusion-Driven Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30877085"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17345,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Ipatasertib (GDC-0068) and Torisel (temsirolimus) inhibited tumor growth in patient-derived xenograft (PDX) models from a patient with an indeterminate epithelioid neoplasm harboring LAMTOR1-AKT1, and tumor growth inhibition continued throughout the duration of treatment (PMID: 30877085).",
            "molecularProfile": {
                "id": 32504,
                "profileName": "LAMTOR1 - AKT1"
            },
            "therapy": {
                "id": 8461,
                "therapyName": "Ipatasertib + Temsirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15377,
                    "pubMedId": 30877085,
                    "title": "Patient-Driven Discovery, Therapeutic Targeting, and Post-Clinical Validation of a Novel AKT1 Fusion-Driven Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30877085"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17349,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of GSK2334470 and Ipatasertib (GDC-0068) demonstrated an additive effect on growth inhibition of cells derived from a patient with an indeterminate epithelioid neoplasm harboring LAMTOR1-AKT1, in culture (PMID: 30877085).",
            "molecularProfile": {
                "id": 32504,
                "profileName": "LAMTOR1 - AKT1"
            },
            "therapy": {
                "id": 8463,
                "therapyName": "GSK2334470 + Ipatasertib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15377,
                    "pubMedId": 30877085,
                    "title": "Patient-Driven Discovery, Therapeutic Targeting, and Post-Clinical Validation of a Novel AKT1 Fusion-Driven Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30877085"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17344,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Torisel (temsirolimus) inhibited mTORC1 signaling and tumor growth in patient-derived xenograft (PDX) models from a patient with an indeterminate epithelioid neoplasm harboring LAMTOR1-AKT1, however, tumors began to regrow after 3 weeks of treatment (PMID: 30877085).",
            "molecularProfile": {
                "id": 32504,
                "profileName": "LAMTOR1 - AKT1"
            },
            "therapy": {
                "id": 936,
                "therapyName": "Temsirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15377,
                    "pubMedId": 30877085,
                    "title": "Patient-Driven Discovery, Therapeutic Targeting, and Post-Clinical Validation of a Novel AKT1 Fusion-Driven Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30877085"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17346,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK2334470 inhibited growth of cells derived from a patient with an indeterminate epithelioid neoplasm harboring LAMTOR1-AKT1, in culture (PMID: 30877085).",
            "molecularProfile": {
                "id": 32504,
                "profileName": "LAMTOR1 - AKT1"
            },
            "therapy": {
                "id": 3662,
                "therapyName": "GSK2334470",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15377,
                    "pubMedId": 30877085,
                    "title": "Patient-Driven Discovery, Therapeutic Targeting, and Post-Clinical Validation of a Novel AKT1 Fusion-Driven Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30877085"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 32504,
            "profileName": "LAMTOR1 - AKT1",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}